WO2005010049A3 - Tgf-beta1 ligands - Google Patents

Tgf-beta1 ligands Download PDF

Info

Publication number
WO2005010049A3
WO2005010049A3 PCT/US2004/018921 US2004018921W WO2005010049A3 WO 2005010049 A3 WO2005010049 A3 WO 2005010049A3 US 2004018921 W US2004018921 W US 2004018921W WO 2005010049 A3 WO2005010049 A3 WO 2005010049A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta1
tgf
ligands
reagents
isolated
Prior art date
Application number
PCT/US2004/018921
Other languages
French (fr)
Other versions
WO2005010049A2 (en
Inventor
Heidi Marie Bradley
Kristine Kay Kikly
Joanne Sloan Lancaster
Scott William Rowlinson
Original Assignee
Lilly Co Eli
Heidi Marie Bradley
Kristine Kay Kikly
Joanne Sloan Lancaster
Scott William Rowlinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Heidi Marie Bradley, Kristine Kay Kikly, Joanne Sloan Lancaster, Scott William Rowlinson filed Critical Lilly Co Eli
Priority to EP04776554A priority Critical patent/EP1646655A2/en
Publication of WO2005010049A2 publication Critical patent/WO2005010049A2/en
Publication of WO2005010049A3 publication Critical patent/WO2005010049A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Isolated and/or recombinant binding compositions, reagents related thereto are provided. Methods of using said reagents and diagnostic kits are also provided.
PCT/US2004/018921 2003-07-09 2004-07-06 Tgf-beta1 ligands WO2005010049A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04776554A EP1646655A2 (en) 2003-07-09 2004-07-06 Tgf-beta1 ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48582003P 2003-07-09 2003-07-09
US60/485,820 2003-07-09

Publications (2)

Publication Number Publication Date
WO2005010049A2 WO2005010049A2 (en) 2005-02-03
WO2005010049A3 true WO2005010049A3 (en) 2005-08-18

Family

ID=34102666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/018921 WO2005010049A2 (en) 2003-07-09 2004-07-06 Tgf-beta1 ligands

Country Status (2)

Country Link
EP (1) EP1646655A2 (en)
WO (1) WO2005010049A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7467177B2 (en) 2003-12-29 2008-12-16 Xilinx, Inc. Mathematical circuit with dynamic rounding
CA2930677A1 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
JP5070200B2 (en) * 2005-04-22 2012-11-07 イーライ リリー アンド カンパニー Antibodies specific for TGFbeta1
ES2379194T3 (en) * 2005-12-23 2012-04-23 Eli Lilly And Company TGF-beta binding antibodies
USRE47123E1 (en) * 2006-07-18 2018-11-13 Sanofi EPHA2 receptor antagonist antibodies
HUE035575T2 (en) * 2006-10-03 2018-05-28 Genzyme Corp Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
ES2612755T3 (en) 2006-11-02 2017-05-18 Acceleron Pharma, Inc. ALK1 receptor and ligand antagonists and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
KR20180029111A (en) 2008-05-02 2018-03-19 악셀레론 파마 인코포레이티드 Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
KR20110044992A (en) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 TVF-β antagonist multi-target binding protein
EP2497782A1 (en) * 2011-03-08 2012-09-12 Alzinova AB Anti oligomer antibodies and uses thereof
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (en) 2011-10-26 2017-04-25 Seattle Children's Res Inst cysteamine in the treatment of fibrotic disease
WO2013166156A2 (en) * 2012-05-01 2013-11-07 The Johns Hopkins University Compositions and methods for treating or preventing osteoarthritis
US20150284452A1 (en) * 2012-11-13 2015-10-08 Iogenetics, Llc Antimicrobial compositions
JP2016512241A (en) 2013-03-14 2016-04-25 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ HCVNS3 recombinant antigen for improved antibody detection and mutants thereof
US9194873B2 (en) 2013-03-14 2015-11-24 Abbott Laboratories HCV antigen-antibody combination assay and methods and compositions for use therein
ES2778201T3 (en) 2013-11-21 2020-08-10 Brigham & Womens Hospital Inc Compositions and methods for treating pulmonary hypertension
US10501532B2 (en) * 2015-10-07 2019-12-10 Obi Pharma, Inc. Carbohydrate antibodies, pharmaceutical compositions and uses thereof
TWI787230B (en) 2017-01-20 2022-12-21 法商賽諾菲公司 Anti-tgf-beta antibodies and their use
AR110755A1 (en) 2017-01-20 2019-05-02 Genzyme Corp BONE DIRECTED ANTIBODIES
CN111213059B (en) 2017-11-06 2024-01-09 豪夫迈·罗氏有限公司 Diagnostic and therapeutic methods for cancer
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013844A1 (en) * 1995-10-06 1997-04-17 Cambridge Antibody Technology Limited Specific binding members for human transforming growth factor beta; materials and methods
WO2000066631A1 (en) * 1999-04-30 2000-11-09 Cambridge Antibody Technology Limited SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013844A1 (en) * 1995-10-06 1997-04-17 Cambridge Antibody Technology Limited Specific binding members for human transforming growth factor beta; materials and methods
WO2000066631A1 (en) * 1999-04-30 2000-11-09 Cambridge Antibody Technology Limited SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ELLINGSWORTH L R ET AL: "TRANSFORMING GROWTH FACTOR-BETAS ARE EQUIPOTENT GROWTH INHIBITORS OF INTERLEUKIN-1-INDUCED THYMOCYTE PROLIFERATION", CELLULAR IMMUNOLOGY, vol. 114, no. 1, 1988, pages 41 - 54, XP009042444, ISSN: 0008-8749 *
FLANDERS K C ET AL: "ANTIBODIES TO PEPTIDE DETERMINANTS IN TRANSFORMING GROWTH FACTOR BETA AND THEIR APPLICATIONS", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 27, 1988, pages 739 - 746, XP002044723, ISSN: 0006-2960 *
LUCAS C ET AL: "THE AUTOCRINE PRODUCTION OF TRANSFORMING GROWTH FACTOR-BETA1 DURING LUMPHOCYTE ACTIVATION A STUDY WITH A MONOCLONAL ANTIBODY-BASED ELISA", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 145, 1 September 1990 (1990-09-01), pages 1415 - 1422, XP000917385, ISSN: 0022-1767 *
Monoclonal anti-TGF-b1 antibody. R&D Systems, Ordering Information, Catalog Number: MAB2401, 29.1.2003. *
SHAH M ET AL: "NEUTRALISATION OF TGF-BETA1 AND TGF-BETA2 OR EXOGENOUS ADDITION OF TGF-BETA3 TO CUTANEOUS RAT WOUNDS REDUCES SCARRING", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 108, no. PART 3, 1 March 1995 (1995-03-01), pages 985 - 1002, XP000609005, ISSN: 0021-9533 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9573995B2 (en) 2013-05-06 2017-02-21 Scholar Rock, Inc. Compositions and methods for growth factor modulation

Also Published As

Publication number Publication date
WO2005010049A2 (en) 2005-02-03
EP1646655A2 (en) 2006-04-19

Similar Documents

Publication Publication Date Title
WO2005010049A3 (en) Tgf-beta1 ligands
WO2006017538A3 (en) Hk1-binding proteins
WO2004037988A3 (en) Methods for synthesizing complementary dna
WO2005107491A3 (en) Multi-lectin affinity chromatography and uses thereof
WO2007133290A8 (en) Anti-ox40l antibodies and methods using same
EP1623011A4 (en) IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
DK1874818T3 (en) TGF-Beta 1-specific antibodies
WO2006020947A9 (en) Phosphonate fluorescent dyes and conjugates
WO2006058237A3 (en) Polymer-coated substrates for binding biomolecules and methods of making and using thereof
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
WO2006028429A3 (en) Peptides for targeting the prostate specific membrane antigen
WO2003050243A3 (en) Novel genes encoding colon cancer antigens
EP1836214A4 (en) Compositions, methods, and kits for enhancing protein expression, solubility and isolation
WO2005087793A3 (en) Immunostimulatory compositions and uses thereof
WO2004013160A3 (en) Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
WO2005123913A3 (en) Reversibly modified thermostable enzyme compositions and methods of making and using the same
WO2006054297A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2005054495A3 (en) Ligand-containing micelles and uses thereof
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
WO2006073971A3 (en) Binding protein with a scaffold for varying specificity
WO2006063028A3 (en) Immunostimulatory compositions and uses thereof
WO2005062947A3 (en) Methods and compositions for identifying rna-binding proteins
AU2003225976A1 (en) Anti-tnf antibodies, compositions, methods and uses
WO2004110365A3 (en) Liver related disease compositions and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004776554

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004776554

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004776554

Country of ref document: EP